Journals / Mikrobiyoloji Bülteni / 2010 / Cilt: 44 - Sayı: 1

Investigation of the in vitro antibacterial effects of statins

Statinlerin in vitro antibakteriyel etkinliğinin araştırılması

Pages
161–163
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The results showed that minimum inhibitory concentration (MIC) values for all isolates were > 128 ug/ml for the two statins tested.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:It was previously shown that statins have anti-inflammatory, immunomodulatory and anti-oxidant effects.
📊
Key Findings & Data:In this study antibacterial activity of the statins were tested against 16 methicillin-susceptible Staphylococcus aureus (MSSA), 16 methicillin-re-sistant S.aureus (MRSA), 16 methicillin-resistant coagulase-negative Staphylococcus (MRCoNS), 9 vancomycin-suscep-tible Enterococcus faecium, 7 vancomycin-susceptible Enterococcus faecalis, 13 vancomycin-resistant E.faecium, 16 extended spectrum beta-lactamase (ESBL) positive Escherichia coll, 16 Pseudomonas aeruginosa, 16 Acinetobacter baumannii, 15 ESBL positive Klebsiella pneumoniae, 6 Stenotrophomonas maltophilia by broth microdilution method according to the Clinical and Laboratory Standards Institute (CLSI) performance and interpretive guidelines.
💡
Conclusion & Impact:The results showed that minimum inhibitory concentration (MIC) values for all isolates were > 128 ug/ml for the two statins tested.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

It was previously shown that statins have anti-inflammatory, immunomodulatory and anti-oxidant effects. This study was aimed to investigate the in-vitro antibacterial effects of simvastatin and atorvastatin. In this study antibacterial activity of the statins were tested against 16 methicillin-susceptible Staphylococcus aureus (MSSA), 16 methicillin-re-sistant S.aureus (MRSA), 16 methicillin-resistant coagulase-negative Staphylococcus (MRCoNS), 9 vancomycin-suscep-tible Enterococcus faecium, 7 vancomycin-susceptible Enterococcus faecalis, 13 vancomycin-resistant E.faecium, 16 extended spectrum beta-lactamase (ESBL) positive Escherichia coll, 16 Pseudomonas aeruginosa, 16 Acinetobacter baumannii, 15 ESBL positive Klebsiella pneumoniae, 6 Stenotrophomonas maltophilia by broth microdilution method according to the Clinical and Laboratory Standards Institute (CLSI) performance and interpretive guidelines. S.aureus ATCC 29213, S.aureus ATCC 25923, S.aureus ATCC 43300, Enterococcus faecalis ATCC 29212, K.pneumoniae ATCC 700603 and E.co-li ATCC 35218 were tested as control strains. The results showed that minimum inhibitory concentration (MIC) values for all isolates were > 128 ug/ml for the two statins tested. However, MIC of simvastatin was 32 ug/ml for S.aureus ATCC 29213 and was 64 ug/ml for S.aureus ATCC 25923 and E.faecalis ATCC 29212 and was > 128 ug/ml for others, but MIC of atorvastatin was > 128 ug/ml for all standard strains. According to these results, we observed that simvastatin and atorvastain had no significant antibacterial effect in vitro. In this study, although no antibacterial effect of statins were determined in vitro, further studies are needed to investigate the combined effect of statins with antibacterial agents in the living organism.

🔖

Cite This Article

ÇOBAN, A. Y., TEKELİ, H. Ö., GÜNEY, A. K., DURUPINAR, B. (2010). Investigation of the in vitro antibacterial effects of statins. Mikrobiyoloji Bülteni, Cilt: 44 - Sayı: 1, 161–163. https://ajindex.com/articles/298871

References (1)

  1. Majumdar SR, McAlister FA, Eurich DT, Padwal RS, Marrie TJ. Statins and outcomes in patients admitted to hospital with community acquired pneumonia: population based prospective cohort study. BMJ 2006; 333: 999-1004. 2.Hackam DG, Mamdani M, Li P, Redelmeier DA. Statins and sepsis in patients with cardiovascular disease: a population-based cohort analysis. Lancet 2006; 367: 413-8. 3.Almog Y, Novack V, Eisinger M, Porath A, Novack L, Gilutz H. The effect of statin therapy on infection-related mortality in patients with atherosclerotic diseases. Crit Care Med 2007; 35: 372-8. 4.Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved Standard M7-A6. 2003, 6th ed. CLSI, Wayne, Pa. 5.Grellier P, Valetin A, Millerioux V, Schrevel J, Rigomer D. 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors lovastatin ve simvastatin inhibit in vitro development of Plasmodium falciparum and Babesia diver-gens in human erythrocytes. Antimicrob Agents Chemother 1994; 38: 1144-8. 6.Pradines B, Torrentino-Madamet M, Fontaine A, et al. Atorvastatin is 10-fold more active in vitro than other statins against Plasmodium falciparum. Antimicrob Agents Chemother 2007; 51: 2654-5. 7.Botelho-Nevers E, Rolain JM, Espinosa L, Raoult D. Statins limit Rickettsia conorii infection in cells. Int J Antimicrob Agents 2008; 32: 344-8. 8.Thomsen RW, Riis A, Kornum JB, Christensen S, johnsen SP, Sorensen HT. Preadmission use of statins and outcomes after hospitalization with pneumoniae: population-based cohort study of 29.900 patients. Arch Intern Med 2008; 168: 2081-7. 9.Falagas ME, Makris GC, Matthaiou DK, Rafailidis PI. Statins for infection and sepsis: a systematic review of the clinical-evidence. J Antimicrob Chemother 2008; 61: 774-85. 10.jerwood S, Cohen J. Unexpected antimicrobial effect of statins. J Antimicrob Chemother 2008; 61: 362-4.